endo-N-[2-(3-methyl-1H-pyrazol-yl)ethyl]carbamic acid tert-butyl ester | 1023300-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: endo-N-[2-(3-methyl-1H-pyrazol-yl)ethyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[2-(3-methyl-1H-pyrazol-yl)ethyl]carbamate；tert-butyl N-[2-(3-methylpyrazol-1-yl)ethyl]carbamate
• CAS: 1023300-44-8
• 化学式: C₁₁H₁₉N₃O₂
• 分子量: 225.291
• InChiKey: GOVUBDVDZISPOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  endo-N-[2-(3-methyl-1H-pyrazol-yl)ethyl]carbamic acid tert-butyl ester 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以94%的产率得到tert-butyl N-[2-(4-bromo-3-methylpyrazol-1-yl)ethyl]carbamate
  参考文献：
  名称：

  2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

  摘要：

  A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl) ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R potency and oral exposure. Analogs from both series, 16a and 17f, show in vivo activity comparable to 1 in our constitutively activated IGF-1R Sal tumor model. This may be the due to the improved protein binding in human and mouse serum for imidazole 16a and the excellent oral exposure of pyrazole 17f. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.049
• 作为产物：
  描述：

  3-(3-甲基-1H-吡唑-1-基)丙酸 、 叔丁醇 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以67%的产率得到endo-N-[2-(3-methyl-1H-pyrazol-yl)ethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924

  摘要：

  A series of IGF-1R inhibitors is disclosed, wherein the (m-chlorophenyl) ethanol side chain of BMS-536924 (1) is replaced with a series of 2-(1H-imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chains. Some analogs show improved IGF-1R potency and oral exposure. Analogs from both series, 16a and 17f, show in vivo activity comparable to 1 in our constitutively activated IGF-1R Sal tumor model. This may be the due to the improved protein binding in human and mouse serum for imidazole 16a and the excellent oral exposure of pyrazole 17f. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.049

文献信息

• [EN] QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS QUINAZOLINE ET QUINOLÉINE, ET UTILISATIONS DE CEUX-CI
  申请人：MILLENNIUM PHARM INC

  公开号：WO2016118565A1

  公开（公告）日：2016-07-28

  This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.

  这项发明提供了式（I）的化合物或其药用盐，其中T、J、R、R4、Rq、o、RA、W和RB及其子集如规范中所述。这些化合物是NAMPT的抑制剂，因此可用于治疗癌症、炎症性疾病和/或T细胞介导的自身免疫疾病。
• Certain chemical entities, compositions, and methods
  申请人：Lu Pu-Ping

  公开号：US20090012126A1

  公开（公告）日：2009-01-08

  Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

  本文描述了调节平滑肌肌球蛋白和/或非肌肉肌球蛋白的化学实体，以及与平滑肌肌球蛋白和/或非肌肉肌球蛋白相关的疾病和病情的化学实体、药物组合物和治疗方法。
• CYCLOPENTYLACRYLAMIDE DERIVATIVE
  申请人：Fukuda Yasumichi

  公开号：US20110160211A1

  公开（公告）日：2011-06-30

  A compound having a hypoglycemic effect is provided. The compound and a pharmaceutically acceptable salt thereof are useful for the treatment or prevention of diabetes, obesity, and the like. The compound is represented by the general formula (1): (wherein R 1 and R 2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C 1 to C 6 alkyl group, a C 1 to C 6 alkoxy group, a C 1 to C 6 alkylsulfanyl group, a C 1 to C 6 alkylsulfinyl group, a C 1 to C 6 alkylsulfonyl group, or a C 1 to C 6 alkoxy-C 1 to C 6 alkylsulfonyl group, and A is a substituted or unsubstituted heteroaryl group).

  提供了一种具有降血糖作用的化合物。该化合物及其药学上可接受的盐可用于治疗或预防糖尿病、肥胖症等疾病。该化合物由一般式（1）表示：（其中R1和R2分别独立地为氢原子、卤素原子、氨基、羟基、羟基氨基、硝基、氰基、磺酰基、C1到C6烷基、C1到C6烷氧基、C1到C6烷基硫基、C1到C6烷基亚砜基、C1到C6烷基磺酰基或C1到C6烷氧基-C1到C6烷基磺酰基；A为取代或未取代的杂环芳基）。
• QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP3247705A1

  公开（公告）日：2017-11-29
• QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP3247705B1

  公开（公告）日：2019-11-20